Shares of Diploma PLC (LON:DPLM – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 3,652.97 ($46.21) and traded as high as GBX 4,152 ($52.52). Diploma shares last traded at GBX 4,152 ($52.52), with a volume of 777,434 shares.
Analysts Set New Price Targets
Several research analysts have commented on the stock. Berenberg Bank lifted their price target on shares of Diploma from GBX 4,400 ($55.65) to GBX 4,700 ($59.45) and gave the stock a “buy” rating in a research note on Monday, May 13th. Shore Capital reissued a “buy” rating on shares of Diploma in a research note on Monday, May 13th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 4,500 ($56.92) target price on shares of Diploma in a report on Tuesday, May 7th. Finally, Barclays restated an “overweight” rating and issued a GBX 4,050 ($51.23) target price on shares of Diploma in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of GBX 3,950 ($49.96).
Diploma Price Performance
Diploma Cuts Dividend
The business also recently declared a dividend, which was paid on Friday, June 7th. Investors of record on Thursday, May 23rd were issued a GBX 17.30 ($0.22) dividend. This represents a yield of 0.44%. The ex-dividend date was Thursday, May 23rd. Diploma’s dividend payout ratio (DPR) is currently 6,705.88%.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Recommended Stories
- Five stocks we like better than Diploma
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- AbbVie Stock: A Perfect Dip for Investors to Buy
- What Are Dividend Contenders? Investing in Dividend Contenders
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.